A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for ...

Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, ...

Australian researchers have demonstrated that the use of a new, less toxic drug combination after stem cell transplants for ...

The FDA granted fast track designation to nuvisertib for those with intermediate or high-risk myelofibrosis, which ...

Cancer incidence rates among members of Generation X were two to three times higher than among people born in the 1940s, ...

Although cancer of the appendix is rare — typically, it's estimated to affect about 1 or 2 people for every 1 million in the ...

Artificial intelligence (AI) is entering the mainstream. The term encompasses a wide variety of machines that can learn from ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the appointment of Enda ...

Johnson & Johnson (J&J) has reported new outcomes from the Phase II RedirecTT-1 trial of bispecific antibodies, Talvey and ...

Striking a balance between life extension and patient values challenges doctors to view treatment refusal as a valid choice, ...

Data presented at EHA 2025 demonstrated that the Epkinly / R-ICE combination produced an 87% ORR in transplant-eligible r/r ...